HealthCare Global Enterprises Limited has informed stock exchanges about an upcoming board meeting scheduled for February 24, 2026. The meeting will consider key matters related to the company’s proposed rights issue.
The company had earlier approved the issuance of equity shares with a face value of ₹10 each through a rights issue for an amount not exceeding ₹425 crore. The decision was taken at the board meeting held on February 17, 2026.
The upcoming meeting on February 24, 2026, will consider and decide specific terms of the rights issue. These include determination of the issue price, payment mechanism, rights entitlement ratio, record date, and timing of the issue.
The rights issue will be offered to eligible shareholders in accordance with the Companies Act, 2013 and the Securities and Exchange Board of India Issue of Capital and Disclosure Requirements Regulations, 2018, along with other applicable laws.
The company stated that the board meeting is being convened in compliance with Regulation 29(1)(d) of the Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations, 2015.
The finalisation of terms will be subject to receipt of in principle approvals from the stock exchanges where the company’s securities are listed and other required regulatory authorities.
HealthCare Global Enterprises Limited is listed on the National Stock Exchange of India Limited under the symbol HCG and on BSE Limited under Scrip Code 539787.
The company operates oncology and healthcare centres across multiple cities including Bengaluru, Mumbai, Kolkata, Chennai, Jaipur, Ahmedabad, and other locations in India and Kenya. Its registered office is located in Bengaluru, Karnataka.
Read More: JSW Infra Share Price Rise Ahead of Feb 20 Board Meet to Consider Fundraising Plan!
As of February 18, 2026, at 11:46 AM, Healthcare Global Enterprises share price on NSE was trading at ₹577.50 down by 0.19% from the previous closing price.
HealthCare Global Enterprises Limited will hold a board meeting on February 24, 2026, to determine the detailed terms of its proposed ₹425 crore rights issue. The outcome will clarify the pricing, entitlement ratio, and schedule, subject to regulatory approvals.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Feb 18, 2026, 12:09 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
EN